

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Block Listing Six Monthly Return**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Scancell Holdings plc		
Number and class of securities originally admitted:		2,880,000 ordinary shares of £0.001 each		
Date of admission:		17 April 2023		
Period of return:	From:	17 October 2023	To:	16 April 2024
Balance of unallotted securities under scheme(s) from previous return:		1,620,000		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		1,000,000		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		620,000		
Total number of securities in issue at the end of the period		928,979,977		

**For further information, please contact:**

**Scancell Holdings plc**

+44 (0) 20 3709 5700

Professor Lindy Durrant, CEO  
Dr Jean-Michel Cosséry, Non-Executive Chairman

**Stifel Nicolaus Europe Limited** (Nominated Adviser and Joint Broker)

+44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)  
Nick Adams/Nick Harland (Corporate Broking)

**WG Partners LLP** (Joint Broker)

+44 (0) 20 3705 9330

David Wilson/Claes Spang/Sathesh Nadarajah/Erlend Sternby

**Panmure Gordon (UK) Limited** (Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

**About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope<sup>®</sup> and ImmunoBody<sup>®</sup> for vaccines and GlyMab<sup>®</sup> and AvidiMab<sup>®</sup> for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope<sup>®</sup> and ImmunoBody<sup>®</sup>) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab<sup>®</sup>) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab<sup>®</sup>).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRBUGDSUBDGSU